Top

Published in:

01-12-2016 | Original Article

Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity

Authors: Zhiqiang Zhang, Yunmin Wang, Jiehan Chen, Qijia Tan, Caijun Xie, Cong Li, Wengang Zhan, Mei Wang

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2016

Abstract

Histone deacetylases (HDACs) can regulate the progression of various cancers, while their roles in glioblastoma multiforme (GBM) are not well known. Our present study investigated the expression of class I HDACs (HDAC1, 2, 3, 8) in GBM U87, A172, U251, and LN229 cells and compared their levels with that in primary normal human astrocytes (NHA) cells. It showed that HDAC2 expression is significantly up-regulated in GBM cells. Silencing of HDAC2 via its specific siRNAs can suppress the in vitro proliferation, migration, and invasion of GBM U87 and A172 cells. Furthermore, silencing of HDAC2 can increase the sensitivity of GBM cells to temozolomide (TMZ), a standard-of-care during clinical GBM treatment. This might be due to that si-HDAC can significantly down-regulate the mRNA and protein expression of MRP1, while has no effect on ABCB1 and ABCG2. Schisandrin B (Sch B), a specific inhibitor of MRP1, can further increase the TMZ sensitivity in HDAC2-knocked down GBM cells. Collectively, our data revealed that targeted HDAC2 can suppress the malignancy of GBM cells and increase their sensitivity of TMZ via down-regulation of MRP1. It suggested that HDAC2 might be a potential target for GBM therapy and improvement in TMZ therapy efficiency.

Arvold ND, Reardon DA (2014) Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 9:357–367PubMedPubMedCentral

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683–2710CrossRefPubMed

Stupp R, Hegi ME (2013) Brain cancer in 2012: molecular characterization leads the way. Nat Rev Clin Oncol. 10:69–70CrossRefPubMed

Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res Off J Am Assoc Cancer Res. 6:2585–2597

Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed

Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM et al (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol Off J Am Soc Clin Oncol. 23:7178–7187CrossRef

Xu Y, Jiang Z, Yin P, Li Q, Liu J (2012) Role for Class I histone deacetylases in multidrug resistance. Exp Cell Res 318:177–186CrossRefPubMed

Zhang J, Zhong Q (2014) Histone deacetylase inhibitors and cell death. Cell Mol Life Sci CMLS. 71:3885–3901CrossRefPubMed

10.

Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280:168–176CrossRefPubMed

11.

Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291–7300PubMed

12.

Ye P, Xing H, Lou F, Wang K, Pan Q, Zhou X et al (2016) Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription. Cancer Chemother Pharmacol 77:613–621CrossRefPubMed

13.

Booth L, Roberts JL, Conley A, Cruickshanks N, Ridder T, Grant S et al (2014) HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biol Ther 15:305–316CrossRefPubMed

14.

Rasmussen RD, Gajjar MK, Jensen KE, Hamerlik P (2016) Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Mol Oncol. 10:751–763CrossRefPubMed

15.

Ge L-C, Chen Z-J, Liu H-Y, Zhang K-S, Liu H, Huang H-B et al (2014) Involvement of activating ERK1/2 through G protein coupled receptor 30 and estrogen receptor α/β in low doses of bisphenol A promoting growth of Sertoli TM4 cells. Toxicol Lett 226:81–89CrossRefPubMed

16.

Tivnan A, Zakaria Z, O’Leary C, Kögel D, Pokorny JL, Sarkaria JN et al (2015) Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci. 9:218CrossRefPubMedPubMedCentral

17.

Sun M, Xu X, Lu Q, Pan Q, Hu X (2007) Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett 246:300–307CrossRefPubMed

18.

Zhang T, Shao Y, Chu T-Y, Huang H-S, Liou Y-L, Li Q et al (2016) MiR-135a and MRP1 play pivotal roles in the selective lethality of phenethyl isothiocyanate to malignant glioma cells. Am J Cancer Res. 6:957–972PubMedPubMedCentral

19.

Shabason JE, Tofilon PJ, Camphausen K (2011) Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 15:2735–2744CrossRefPubMedPubMedCentral

20.

Tang Y, Yacoub A, Hamed HA, Poklepovic A, Tye G, Grant S et al (2012) Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biol Ther 13:567–574CrossRefPubMedPubMedCentral

21.

Barazzuol L, Jeynes JCG, Merchant MJ, Wéra A-C, Barry MA, Kirkby KJ et al (2015) Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays. Int J Radiat Biol 91:90–98CrossRefPubMed

22.

Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P et al (2013) Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol. 31:1770–1779CrossRefPubMed

23.

Lee Y-H, Seo D, Choi K-J, Andersen JB, Won M-A, Kitade M et al (2014) Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res 74:4752–4761CrossRefPubMedPubMedCentral

24.

Hrzenjak A, Moinfar F, Kremser M-L, Strohmeier B, Staber PB, Zatloukal K et al (2006) Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5:2203–2210CrossRefPubMed

25.

Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ et al (2011) Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS ONE 6:e28103CrossRefPubMedPubMedCentral

26.

Fan T-Y, Wang H, Xiang P, Liu Y-W, Li H-Z, Lei B-X et al (2014) Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma. Int J Clin Exp Pathol. 7:6662–6670PubMedPubMedCentral

27.

Kim H, Kim S-N, Park Y-S, Kim NH, Han JW, Lee HY et al (2011) HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. Int J Oncol 38:807–812PubMed

28.

Chao KC, Chang CC, Yen MS, Wang PH (2010) Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells. Eur J Gynaecol Oncol 31:402–410PubMed

29.

Zhao H, Yu Z, Zhao L, He M, Ren J, Wu H et al (2016) HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy. Jpn J Clin Oncol 46:893–902CrossRefPubMed

30.

Allen M, Bjerke M, Edlund H, Nelander S, Westermark B (2016) Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med 8:354re3–354re3

31.

Kusaczuk M, Krętowski R, Stypułkowska A, Cechowska-Pasko M (2016) Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor—belinostat—in glioblastoma cell lines: a preliminary report. Invest New Drugs 34:552–564CrossRefPubMedPubMedCentral

Title: Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity
Authors: Zhiqiang Zhang
Yunmin Wang
Jiehan Chen
Qijia Tan
Caijun Xie
Cong Li
Wengang Zhan
Mei Wang
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3188-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial

Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma

Eriocitrin from lemon suppresses the proliferation of human hepatocellular carcinoma cells through inducing apoptosis and arresting cell cycle

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases

Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer